Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2

This study has been terminated.
VA Boston Healthcare System
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: June 2, 2015
Last verified: January 1996

The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Risperidone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Serotonin/Dopamine Antagonism of Cocaine Effect

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Urine toxicology for cocaine
  • Analog mood scales
  • POMS
  • EPS sx

Estimated Enrollment: 0
Study Start Date: January 1996
Detailed Description:

Risperidone in low doses is compared with placebo in a 6-week randomized trial. Subjects also receive supportive counseling. Outcome measure include rating of behavior, mood, drug abuse, global function, and urine toxicology.


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Cocaine abuse or dependence

Exclusion Criteria:

Dependence on other drugs. Major psychiatric illness

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000310

United States, Rhode Island
Brown University School of Medicine
Providence, Rhode Island, United States, 2906
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Boston Healthcare System
Principal Investigator: Lawrence Price, M.D. Brown University
  More Information

No publications provided Identifier: NCT00000310     History of Changes
Other Study ID Numbers: NIDA-09330-2, R01-09330-2
Study First Received: September 20, 1999
Last Updated: June 2, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders processed this record on October 02, 2015